| CAS NO: | 475-67-2 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 20mg | 电议 |
| Cas No. | 475-67-2 |
| 别名 | 异紫堇定碱 |
| Canonical SMILES | COC1=C2C3=C(C=C1OC)CCN(C)[C@@]3([H])CC4=CC=C(OC)C(O)=C24 |
| 分子式 | C20H23NO4 |
| 分子量 | 341.4 |
| 溶解度 | Chloroform: 10 mg/ml |
| 储存条件 | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC)[1]. Isocorydine (0-400 ug/ml; 48 hours) show a significant decrease in the IC50 for ICD and DOX, the CI values are 0.605, 0.644, 0.804, and 0.707 respectively for Huh-7, Hep-G2, SNU-449 and SNU-387[1]. Isocorydine (0-400 ug/ml; 48 hours) abrogates DOX-induced upregulation of mesenchymal markers and the downregulation of epithelial markers in human HCC cell lines[1]. Cell Viability Assay[1] Cell Line: Huh-7, Hep-G2 , SNU-387, SNU-449 cells Isocorydine (intraperitoneal injection; 0.4 mg/kg; every 2 days for 2 weeks) retards the tumor growth, but the combined treatment of Doxorubicin (DOX) or ICD significantly inhibits tumor growth[1]. Animal Model: Female nude mice[1] [1]. Pan JX, et al. Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. Am J Cancer Res. 2018 Jan 1;8(1):154-164. eCollection 2018. |
m.cnreagent.com